{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:55:52Z","timestamp":1781528152198,"version":"3.54.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.msard.2026.107130","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T07:54:26Z","timestamp":1773042866000},"page":"107130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Prevalence and clinical implications of abnormal autoantibodies in Omani patients with multiple sclerosis: A retrospective cross-sectional study"],"prefix":"10.1016","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2732-1736","authenticated-orcid":false,"given":"Mohamed","family":"Al-Maskari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2851-8157","authenticated-orcid":false,"given":"Abdullah","family":"Al-Asmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Mazharul","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raiyan","family":"Al-Hidabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mortada","family":"Elyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalila","family":"AlShekaili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmood","family":"Al-Kindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba Sadeghi","family":"Rashed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107130_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103034","article-title":"Epidemiology of multiple sclerosis in Oman: a hospital-based study","volume":"53","author":"Al-Senani","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107130_bib0001","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s41983-021-00284-6","article-title":"Prevalence of antinuclear antibody in patients with multiple sclerosis: a case-control study","volume":"57","author":"Alnajashi","year":"2021","journal-title":"Egypt. J. Neurol. Psychiatry Neurosurg."},{"key":"10.1016\/j.msard.2026.107130_bib0003","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/jalm\/jfab140","article-title":"The international consensus on ANA patterns (ICAP) in 2021","volume":"7","author":"Chan","year":"2022","journal-title":"J. Appl. Lab. Med."},{"key":"10.1016\/j.msard.2026.107130_bib0004","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-17254-0","article-title":"Antinuclear antibodies in early multiple sclerosis reflect systemic lupus erythematosus shared risk factors","volume":"15","author":"Corsten","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.msard.2026.107130_bib0005","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/art.41214","article-title":"Increasing prevalence of antinuclear antibodies in the United States","volume":"72","author":"Dinse","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.msard.2026.107130_bib0007","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16558","article-title":"Autoimmune screening panel in patients with multiple sclerosis: a Vienna MS database study","volume":"32","author":"F\u00f6ttinger","year":"2025","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2026.107130_bib0006","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1865","article-title":"Serum antinuclear antibodies associate with worse prognosis in AQP4-positive neuromyelitis optica spectrum disorder","volume":"11","author":"Fan","year":"2021","journal-title":"Brain Behav."},{"key":"10.1016\/j.msard.2026.107130_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocn.2025.111493","article-title":"A broad range of antiphospholipid IgM are elevated across different multiple sclerosis clinical phenotypes","volume":"140","author":"Frese","year":"2025","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.msard.2026.107130_bib0009","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jneuroim.2007.04.008","article-title":"Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis","volume":"187","author":"Garg","year":"2007","journal-title":"J. Neuroimmunol."},{"issue":"3","key":"10.1016\/j.msard.2026.107130_bib0010","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00415-019-09614-4","article-title":"Effects of IVIg treatment on autoantibody testing in neurological patients: marked reduction in sensitivity but reliable specificity","volume":"267","author":"Gr\u00fcter","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2026.107130_bib0011","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.curtheres.2014.06.004","article-title":"The prevalence of antinuclear antibodies in the general population of China: a cross-sectional study","volume":"76","author":"Guo","year":"2014","journal-title":"Curr. Ther. Res. \u2013 Clin. Exp."},{"key":"10.1016\/j.msard.2026.107130_bib0012","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211007687","article-title":"Inflammation in multiple sclerosis","volume":"14","author":"Haase","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2026.107130_bib0013","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s42466-024-00351-2","article-title":"Prevalence of comorbid autoimmune diseases in newly diagnosed MS","volume":"6","author":"Jendretzky","year":"2024","journal-title":"Neurol. Res. Pract."},{"key":"10.1016\/j.msard.2026.107130_bib0014","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1111\/jth.13379","article-title":"IgG\/IgM antiphospholipid antibodies in APS classification: association with thrombosis","volume":"14","author":"Kelchtermans","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.msard.2026.107130_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105639","article-title":"Relevance of antinuclear antibody in diagnosis and characteristics of multiple sclerosis","volume":"87","author":"Koshorek","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107130_bib0016","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s10072-014-1823-4","article-title":"High frequency of antiphospholipid antibodies in relapse of multiple sclerosis","volume":"35","author":"Koudriavtseva","year":"2014","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2026.107130_bib0017","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/diagnostics14030320","article-title":"Comprehensive exploration of antinuclear antibodies","volume":"14","author":"Kraev","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.msard.2026.107130_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1746-1596-4-1","article-title":"Antinuclear antibodies and their detection methods in diagnosis of connective tissue diseases: a journey revisited","volume":"4","author":"Kumar","year":"2009","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.msard.2026.107130_bib0019","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.neurol.2021.11.016","article-title":"Antinuclear antibodies positivity is not rare during multiple sclerosis","volume":"178","author":"Mejdoub","year":"2022","journal-title":"Rev. Neurol. (Paris)"},{"issue":"6","key":"10.1016\/j.msard.2026.107130_bib0020","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.semarthrit.2016.09.010","article-title":"Relevance of antiphospholipid antibodies in multiple sclerosis: systematic review and meta-analysis","volume":"46","author":"Merashli","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.msard.2026.107130_bib0021","series-title":"Epidemiology Report","year":"2023"},{"key":"10.1016\/j.msard.2026.107130_bib0022","doi-asserted-by":"crossref","first-page":"60","DOI":"10.5603\/PJNNS.a2023.0047","article-title":"Clinical significance and prognostic value of serum autoantibody tests in multiple sclerosis","volume":"58","author":"\u00d6ncel","year":"2024","journal-title":"Neurol. Neurochir. Pol."},{"key":"10.1016\/j.msard.2026.107130_bib0023","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41584-020-0480-7","article-title":"New insights into the role of antinuclear antibodies in systemic lupus erythematosus","volume":"16","author":"Pisetsky","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.msard.2026.107130_bib0025","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1006\/jaut.2000.0367","article-title":"Prevalence and clinical significance of antiphospholipid antibodies in multiple sclerosis: a study of 89 patients","volume":"14","author":"Roussel","year":"2000","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.msard.2026.107130_bib0026","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clim.2017.04.014","article-title":"Effector and regulatory B cells in multiple sclerosis","volume":"184","author":"Staun-Ram","year":"2017","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.msard.2026.107130_bib0027","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1177\/0961203311427550","article-title":"Antinuclear and antiphospholipid antibodies in patients with multiple sclerosis","volume":"21","author":"Szmyrka-Kaczmarek","year":"2012","journal-title":"Lupus"},{"issue":"1\u20132","key":"10.1016\/j.msard.2026.107130_bib0028","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000358218","article-title":"Combined screening for serum anti-nuclear and anti-aquaporin-4 antibodies improves diagnostic accuracy for distinguishing neuromyelitis optica from multiple sclerosis","volume":"72","author":"Wu","year":"2014","journal-title":"Eur. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2026.107130_bib0029","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1179\/1743132812Y.0000000076","article-title":"Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study","volume":"34","author":"Zivadinov","year":"2012","journal-title":"Neurol. Res."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826001665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826001665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:24:07Z","timestamp":1781526247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826001665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":28,"alternative-id":["S2211034826001665"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107130","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence and clinical implications of abnormal autoantibodies in Omani patients with multiple sclerosis: A retrospective cross-sectional study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107130","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107130"}}